You are here

Merck

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

Endpoints

Thu, 10/21/21 - 09:31 am

Bristol Myers Squibb

Keytruda maker Merck rolls web series to illuminate triple-negative breast cancer and Black women

Fierce Pharma

Wed, 10/20/21 - 06:49 pm

pharma marketing

triple negative breast cancer

Merck Recalls 22,000 Vials Of Cubicin After Discovering Glass Particles

BioSpace

Wed, 10/20/21 - 10:27 am

product recalls

Gates Foundation will provide $120 million to ensure generic production of Merck’s Covid-19 pill

Stat

Wed, 10/20/21 - 10:07 am

Gates Foundation

Biotech innovation lab formed by AstraZeneca, Merck, Pfizer and Teva

Biopharma Reporter

Mon, 10/18/21 - 10:57 am

artificial intelligence

Teva Pharmaceutical

Merck’s Covid-19 Pill Set for Review by FDA Advisory Panel

Bloomberg

Fri, 10/15/21 - 11:08 am

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention

BioSpace

Thu, 10/14/21 - 11:12 pm

Bristol Myers Squibb

Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut

Endpoints

Wed, 10/13/21 - 10:48 pm

cervical cancer

Big Pharma companies join hands with Amazon on new Israel-based AI incubator

Endpoints

Wed, 10/13/21 - 11:00 am

Teva Pharmaceutical

artificial intelligence

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Fierce Pharma

Tue, 10/12/21 - 11:35 pm

Merck’s breakthrough COVID pill faces a risk: the virus could outsmart it

Fortune

Tue, 10/12/21 - 11:02 am

viral resistance

Merck Reportedly Plans To Double Production Of New Covid-Fighting Pill As Wealthy Countries Corner Scarce Supplies

Forbes

Tue, 10/12/21 - 10:57 am

drug manufacturing

Merck asks FDA to authorize promising anti-COVID pill

NPR

Mon, 10/11/21 - 10:29 am

Ridgeback Therapeutics

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

Motley Fool

Sat, 10/9/21 - 11:05 pm

pneumococcal disease

Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?

Motley Fool

Fri, 10/8/21 - 10:58 am

Ridgeback Therapeutics

Atea Pharmaceuticals

Is an Acquisition of Acceleron a Smart Move for Merck?

Motley Fool

Fri, 10/8/21 - 10:35 am

Biopharma needs a biggie to avoid a down deal year

EP Vantage

Thu, 10/7/21 - 11:07 am

Biogen, mRNA players on Merck's M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FT

Fierce Pharma

Wed, 10/6/21 - 11:26 pm

Mirati Therapeutics

Merck’s Davis Looking to Diversify in Preparation for Keytruda Patent Cliff

BioSpace

Wed, 10/6/21 - 11:23 pm

Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?

Motley Fool

Wed, 10/6/21 - 10:53 am

Pages